Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific Will Lean On Quadripolar, S-ICD To Revive Sagging U.S. CRM Sales

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific reported disappointing first-quarter results for its cardiac rhythm management division, mostly due to price erosion in the U.S and the lack of a quadripolar CRT-D device. But the firm argues that the new S-ICD and forthcoming quadripolar CRT-D products may help turn the business around soon.

You may also be interested in...

Boston Scientific Gets Early Nod For Next Gen S-ICD

Boston's Emblem S-ICD upgrade was approved by FDA and in Europe earlier than anticipated.

S-ICD Sales Exceeding Expectations, Boston Scientific Reports

The company said when S-ICD launched that it expected the device to be a major growth driver, and that appears to be working out so far. Boston Scientific now expects the leadless implantable defibrillator to bring in $100 million in revenue this year.

Boston Scientific Announces Six ICD/CRT-D Approvals

Boston Scientific announced FDA approval of the Dynagen Mini and Inogen Mini ICDs, which it claims are the thinnest and smallest ICDs available, and the Dynagen X4 and Inogen X4 quadripolar CRT-Ds.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts